Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Price history
Loading TRIB daily closes…
Loading price history…
Pipeline assets
CGM+
Stage not disclosed · ActiveModality: biosensor device
Indications
continuous glucose monitoring (diabetes)(Stage not disclosed)
Catalysts
— 2026
Status note Next-generation continuous glucose monitoring biosensor platform acquired from Waveform (January 2024). Advancing through final design stages; pivotal clinical trials planned for 2026.
PrePsia
Stage not disclosed · ActiveModality: in vitro diagnostic (biomarker)
Indications
preeclampsia risk assessment(Stage not disclosed)
Status note Preeclampsia-risk assessment technology acquired via Metabolomics Diagnostics Ltd. (September 2024). 2025 activities directed toward continued development, validation and regulatory preparation.
EpiCapture
Stage not disclosed · ActiveModality: in vitro diagnostic (molecular)
Indications
prostate cancer (prognostic, progression to aggressive disease)(Stage not disclosed)
Status note Non-invasive urine-based prognostic test for progression to aggressive prostate cancer, acquired October 2024. Two clinical studies planned to strengthen clinical claims; being prepared for submission to the New York State Department of Health as a laboratory-developed test.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.